Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

Description of the Age-Related Eye Disease Study 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial.

Collaborators (349)

Author information

Affiliations

  • 1. Scheie EyeInstitute, University ofPennsylvania, Philadelphia, PA 19104-3309, USA.
      Authors
    • Ying GS 1
    (1 author)

ORCIDs linked to this article

Archives of Ophthalmology (Chicago, Ill. : 1960), 01 Sep 2009, 127(9):1147-1151
https://doi.org/10.1001/archophthalmol.2009.189 PMID: 19752423 

Abstract 

Objective

To describe characteristics of the Age-Related Eye Disease Study (AREDS) 9-step severity scale applied to participants in the Complications of Age-related Macular Degeneration Prevention Trial (CAPT).

Methods

Eligibility criteria for CAPT required 10 or more large (>or=125 microm) drusen in each eye. Readers graded baseline photographs from all participants and all follow-up photographs from 402 untreated eyes. Drusen and pigment characteristics were used to assign the AREDS scale score. Choroidal neovascularization was identified from fluorescein angiograms. Geographic atrophy involving the macular center was identified from color photographs.

Results

Among 1001 untreated eyes, 90% were at steps 5 to 7 at baseline. The 5-year incidence of advanced age-related macular degeneration (AMD) increased with each step from 8% (step 4) to 40% (steps 8 and 9 combined). These rates were similar to those reported in AREDS. Among 261 eyes with all 5 annual photograph gradings available and without progression to advanced AMD, 55% of eyes had scores that indicated improvement at least once. Before progression to advanced AMD, only 32% of 141 eyes either went through step 8 or 9 or had an increase of 2 or more steps from baseline.

Conclusions

The AREDS 9-step severity scale was predictive of development of advanced AMD. The AREDS scale has deficiencies as a surrogate outcome for progression to advanced AMD.

Full text links 

Read article at publisher's site: https://doi.org/10.1001/archophthalmol.2009.189

Free to read at archopht.ama-assn.org
http://archopht.ama-assn.org/cgi/content/abstract/127/9/1147

Subscription required at archopht.ama-assn.org
http://archopht.ama-assn.org/cgi/content/full/127/9/1147

Citations & impact 

Impact metrics

13
Citations
Jump to Citations

Citations of article over time

Smart citations by scite.ai
Smart citations by scite.ai include citation statements extracted from the full text of the citing article. The number of the statements may be higher than the number of citations provided by EuropePMC if one paper cites another multiple times or lower if scite has not yet processed some of the citing articles.
Explore citation contexts and check if this article has been supported or disputed.
https://scite.ai/reports/10.1001/archophthalmol.2009.189

Supporting
Mentioning
Contrasting
0
14
0

Article citations

Go to all (13) article citations

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.

Funding 

Funders who supported this work.

NEI NIH HHS (3)